Grupo Televisa S.A.B Stock To Go Ex-dividend Tomorrow (TV)

NEW YORK ( TheStreet) -- The ex-dividend date for Grupo Televisa S.A.B (NYSE: TV) is tomorrow, December 18, 2013. Owners of shares as of market close today will be eligible for a dividend of 13 cents per share. At a price of $29.19 as of 9:50 a.m. ET, the dividend yield is 0.8%.

The average volume for Grupo Televisa S.A.B has been 1.6 million shares per day over the past 30 days. Grupo Televisa S.A.B has a market cap of $17.01 billion and is part of the services sector and media industry. Shares are up 11.6% year to date as of the close of trading on Monday.

Grupo Televisa, S.A.B. operates as a media company. The company has a P/E ratio of 21.2, above the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Grupo Televisa S.A.B as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Grupo Televisa S.A.B Ratings Report.

See our dividend calendar or top-yielding stocks list.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)